Vitrolife AB (VITR) AI Stock Analysis

• Market Cap: kr18.35B
• Dividend Yield: 0.81%
• Average Volume (3M): 118.46K
• Price to Earnings (P/E): 40.3
• Beta (1Y): 0.77
• Revenue Growth: 0.14%
• EPS Growth: N/A
• Country: SE
• Employees: 1,150
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Devices
• EPS (TTM): 0.74
• Shares Outstanding: 135,447,190
• 10 Day Avg. Volume: 91,558
• 30 Day Avg. Volume: 118,456
• PEG Ratio: -0.50
• Price to Book (P/B): 2.13
• Price to Sales (P/S): 8.07
• P/FCF Ratio: 32.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr142.00
• Price Target Upside: 5.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: kr142.00 ▲(5.19% Upside)

Vitrolife AB's overall stock score is primarily influenced by its strong financial stability and profitability, despite recent growth challenges. Technical indicators suggest a bearish trend, and the high P/E ratio indicates potential overvaluation. The lack of earnings call data and corporate events means these factors did not impact the score.

Vitrolife AB Business Overview & Revenue Model

Company Description

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Vitrolife generates revenue through multiple key streams related to its core offerings in the fertility market. The primary revenue source comes from the sale of its specialized culture media and consumables, which are essential for embryo culture and preservation during IVF treatments. Additionally, the company earns income from laboratory equipment sales, including incubators and other high-tech devices used in ART clinics. A significant part of its revenue is also derived from partnerships with fertility clinics and hospitals, where they provide ongoing support, training, and maintenance for their products. Furthermore, Vitrolife invests in research and development to innovate and expand its product portfolio, which helps in maintaining a competitive edge and attracting new customers, ultimately contributing to its overall earnings.

Vitrolife AB Financial Statement Overview

Summary

Vitrolife AB shows strong profitability with a stable gross profit margin and healthy EBIT and EBITDA margins. The balance sheet reflects financial stability with low leverage. Robust cash flow management supports financial health, though stagnant revenue growth and slight declines in net income and ROE present challenges.

Income Statement

Vitrolife AB shows strong profitability with a consistent Gross Profit Margin of around 57% in the TTM period. The EBIT and EBITDA margins are healthy, indicating efficient cost management. However, revenue growth is stagnant, and net income has slightly declined in the TTM compared to the previous annual report, signaling potential concerns in sustaining growth momentum.

Balance Sheet

The company's balance sheet reveals a strong equity position with a high Equity Ratio of approximately 79% in the TTM. The Debt-to-Equity ratio is manageable at 0.15, reflecting low leverage and financial stability. However, Return on Equity has slightly declined in the TTM period, suggesting room for improved profitability on equity.

Cash Flow

Vitrolife AB demonstrates robust cash management with a positive Free Cash Flow and a solid Operating Cash Flow to Net Income Ratio of 1.56 in the TTM period. Despite a decrease in Free Cash Flow due to reduced Operating Cash Flow, the company's cash generation capabilities remain strong, supporting its financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.54B	3.61B	3.51B	3.23B	1.68B	1.25B
Gross Profit	2.08B	2.14B	1.98B	1.78B	1.05B	767.67M
EBITDA	906.00M	783.00M	-3.19B	993.00M	579.60M	438.65M
Net Income	455.00M	513.00M	-3.85B	394.00M	341.00M	286.85M
Balance Sheet
Total Assets	16.86B	17.45B	16.33B	20.55B	19.43B	2.31B
Cash, Cash Equivalents and Short-Term Investments	921.00M	1.14B	861.00M	578.00M	630.09M	973.57M
Total Debt	1.99B	2.09B	2.09B	2.23B	2.48B	62.40M
Total Liabilities	3.57B	3.81B	3.61B	3.81B	4.09B	288.07M
Stockholders Equity	13.28B	13.64B	12.72B	16.74B	15.32B	2.01B
Cash Flow
Free Cash Flow	648.00M	907.00M	638.00M	549.00M	321.86M	336.36M
Operating Cash Flow	694.00M	907.00M	757.00M	636.00M	384.31M	356.45M
Investing Cash Flow	-291.00M	-377.00M	-124.00M	-144.00M	-6.52B	-20.22M
Financing Cash Flow	-281.00M	-286.00M	-300.00M	-582.00M	5.75B	-26.61M

Vitrolife AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 135.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Negative. The current price of 135 is below the 20-day moving average (MA) of 142.78, below the 50-day MA of 144.42, and below the 200-day MA of 181.70, indicating a bearish trend. The MACD of -2.29 indicates Positive momentum. The RSI at 37.74 is Neutral, neither overbought nor oversold. The STOCH value of 4.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VITR.

Vitrolife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	54 Neutral	kr18.35B	40.33	3.46%	0.81%	0.14%	―
Sector *	46 Neutral	C$212.58M	-2.80	-24.76%	3.13%	19.77%	0.53%
0GZV	―	kr53.86B	35.88	4.94%	―	―	―
CLLKF	―	$265.94M	―	-10.56%	―	―	―
CLVSF	―	$413.44M	28.49	18.65%	1.31%	―	―
XVIPF	―	$622.49M	58.77	5.17%	―	―	―
61L0	―	€6.10B	121.50	32.07%	―	―	―

Vitrolife AB Corporate Events

Vitrolife AB Reports Q2 2025 Results Amid Currency Challenges

Vitrolife AB reported a flat growth in local currencies for the second quarter of 2025, with a notable impact from currency fluctuations leading to a 7% decrease in sales in SEK. The company saw a strong performance in its Consumables segment with a 9% growth, while Technologies and Genetics saw declines. Despite the challenging currency environment, Vitrolife acquired a leading stake in AutoIVF and secured a EUR 300 million loan to refinance existing debt and support corporate purposes, indicating strategic moves to strengthen its market position.